Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy.

Benjamin D MedinaBeatrix Hyemin ChoiKathy G RodogiannisUna MoranRichard L ShapiroAnna PavlickIman OsmanRussell S Berman Ann Y Lee

Published in: Journal of surgical oncology (2020)

Metastasectomy for melanoma is associated with improved OS in patients that respond to targeted molecular or immunotherapy. Resection should be strongly considered in this cohort as multimodality treatment results in excellent OS.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
cancer therapy
skin cancer
patient reported